×
验证码:
换一张
忘记密码?
记住我
CORC
首页
科研机构
检索
知识图谱
申请加入
托管服务
登录
注册
在结果中检索
科研机构
上海药物研究所 [7]
内容类型
期刊论文 [7]
发表日期
2021 [2]
2020 [2]
2019 [2]
2017 [1]
×
知识图谱
CORC
开始提交
已提交作品
待认领作品
已认领作品
未提交全文
收藏管理
QQ客服
官方微博
反馈留言
浏览/检索结果:
共7条,第1-7条
帮助
限定条件
专题:上海药物研究所
第一署名单位
第一作者单位
通讯作者单位
已选(
0
)
清除
条数/页:
5
10
15
20
25
30
35
40
45
50
55
60
65
70
75
80
85
90
95
100
排序方式:
请选择
发表日期升序
发表日期降序
提交时间升序
提交时间降序
题名升序
题名降序
作者升序
作者降序
LS-106, a novel EGFR inhibitor targeting C797S, exhibits antitumor activities both in vitro and in vivo
期刊论文
CANCER SCIENCE, 2021, 页码: 12
作者:
Liu, Yingqiang
;
Lai, Mengzhen
;
Li, Shan
;
Wang, Yanan
;
Feng, Fang
收藏
  |  
浏览/下载:60/0
  |  
提交时间:2022/01/18
C797S
epidermal growth factor receptor
fourth-generation EGFR TKI
non-small cell lung cancer
osimertinib resistance
Biomimetic codelivery overcomes osimertinib-resistant NSCLC and brain metastasis via macrophage-mediated innate immunity
期刊论文
JOURNAL OF CONTROLLED RELEASE, 2021, 卷号: 329, 页码: 1249-1261
作者:
Zhao, Pengfei
;
Zhang, Jiaxin
;
Wu, Aihua
;
Zhang, Meng
;
Zhao, Yuge
收藏
  |  
浏览/下载:107/0
  |  
提交时间:2021/05/24
Brain targeting delivery
Tumor-associated macrophage
Osimertinib resistance
Brain metastasis
Innate immunity
Combination therapy
Safety, Clinical Activity, and Pharmacokinetics of Al flutinib (AST2818) in Patients With Advanced NSCLC With EGFR T790M Mutation
期刊论文
JOURNAL OF THORACIC ONCOLOGY, 2020, 卷号: 15, 期号: 6, 页码: 1015-1026
作者:
Shi, Yuankai
;
Zhang, Shucai
;
Hu, Xingsheng
;
Feng, Jifeng
;
Ma, Zhiyong
收藏
  |  
浏览/下载:36/0
  |  
提交时间:2020/12/24
Alflutinib
NSCLC
EGFR T790M mutation
Efficacy
Safety
2-Oxo-3,4-dihydropyrimido[4,5-d] pyrimidines as new reversible inhibitors of EGFR C797S (Cys797 to Ser797) mutant
期刊论文
CHINESE CHEMICAL LETTERS, 2020, 卷号: 31, 期号: 5, 页码: 1281-1287
作者:
Hu, Xianglong
;
Xun, Qiuju
;
Zhang, Tao
;
Zhu, Su-Jie
;
Li, Qian
收藏
  |  
浏览/下载:45/0
  |  
提交时间:2020/07/01
EGFR(C797S) mutant
SARs
2-Oxo-3,4-dihydropyrimido[4,5-d] pyrimidine
Clinical resistance
Fourth-generation inhibitors
SHR-A1403, a novel c-mesenchymal-epithelial transition factor (c-Met) antibody-drug conjugate, overcomes AZD9291 resistance in non-small cell lung cancer cells overexpressing c-Met
期刊论文
CANCER SCIENCE, 2019, 页码: 11
作者:
Tong, Mengya
;
Gao, Mingzhao
;
Xu, Yongping
;
Fu, Li
;
Li, Yun
收藏
  |  
浏览/下载:21/0
  |  
提交时间:2020/07/01
AZD9291
c-Met ADC
c-Met overexpression
resistance
SHR-A1403
Structure-Based Design of 5-Methylpyrimidopyridone Derivatives as New Wild-Type Sparing Inhibitors of the Epidermal Growth Factor Receptor Triple Mutant (EGFR(L858R/T790M/C797S))
期刊论文
JOURNAL OF MEDICINAL CHEMISTRY, 2019, 卷号: 62, 期号: 15, 页码: 7302-7308
作者:
Shen, Jiayi
;
Zhang, Tao
;
Zhu, Su-Jie
;
Sun, Min
;
Tong, Linjiang
收藏
  |  
浏览/下载:30/0
  |  
提交时间:2020/07/01
Reprogramming Tumor-Associated Macrophages To Reverse EGFR(T790M) Resistance by Dual-Targeting Codelivery of Gefitinib/Vorinostat
期刊论文
NANO LETTERS, 2017, 卷号: 17, 期号: 12, 页码: 7684-7690
作者:
Peng, Huige
;
Chen, Binfan
;
Huang, Wei
;
Tang, Yubo
;
Jiang, Yifan
收藏
  |  
浏览/下载:65/0
  |  
提交时间:2019/01/08
Tumor-associated macrophages
gefitinib
vorinostat
EGFR(T790M)
nonsmall cell lung cancer
drug resistance
©版权所有 ©2017 CSpace - Powered by
CSpace